Valuation: Lexeo Therapeutics, Inc.

Market Cap 257M 230M 213M 193M 360M 24.46B 365M 2.55B 1.01B 12.8B 964M 943M 40.63B P/E 2026 *
-2.57x
P/E 2027 * -2.28x
Enterprise Value 79.09M 70.96M 65.61M 59.42M 111M 7.53B 112M 784M 312M 3.94B 297M 291M 12.51B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lexeo Therapeutics, Inc.

1 day+9.06%
1 week+4.33%
Current month-7.40%
1 month-0.32%
3 months-28.70%
6 months-46.13%
Current year-68.48%
1 week 2.65
Extreme 2.65
3.14
1 month 2.55
Extreme 2.55
3.69
Current year 2.55
Extreme 2.55
10.75
1 year 2.55
Extreme 2.55
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 01/01/2020
Director of Finance/CFO 50 15/08/2025
Chief Tech/Sci/R&D Officer 62 20/01/2026
Director TitleAgeSince
Director/Board Member 46 01/01/2020
Chairman 72 01/01/2021
Director/Board Member 61 01/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
24/9/26 Free

Chief Operating Officer

54,750 0.0697%
24/9/26 Free

Chief Financial Officer

54,750 0.0697%
24/9/26 Free

Chief Technology Officer

54,750 0.0697%
Change 5-day change 1-year change 3-year change Capi.($)
+9.06%+4.33%-68.95% - 257M
+0.65%-3.36%+36.98%+60.50% 64.14B
+0.40%+2.07%+11.58%+82.81% 55.53B
+0.51%+0.99%+10.45%+100.19% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-4.51%+47.63%+107.12%+92.73% 34.47B
-2.94%-0.62%+22.96%-10.93% 24.23B
Average +1.01%+4.11%+40.15%+162.12% 39.28B
Weighted average by Cap. +0.40%+3.49%+49.08%+159.87%

Financials

2026 *2027 *
Net sales - -
Net income -104M -93.07M -86.05M -77.93M -146M -9.88B -147M -1.03B -410M -5.17B -389M -381M -16.41B -130M -117M -108M -97.68M -182M -12.38B -185M -1.29B -514M -6.48B -488M -478M -20.57B
Net Debt -178M -159M -147M -133M -249M -16.92B -252M -1.76B -702M -8.86B -667M -653M -28.11B -305M -274M -253M -229M -428M -29.08B -434M -3.03B -1.21B -15.22B -1.15B -1.12B -48.3B
Projected Income Statement - Annual - Lexeo Therapeutics, Inc.
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
63
Date Price Change Volume
28/10/26 USD 3.130 +9.06% 1,198,378
27/10/26 USD 2.870 +6.30% 2,684,076
26/10/26 USD 2.700 -3.57% 1,162,581
23/10/26 USD 2.800 -3.11% 619,383
22/10/26 USD 2.890 -3.67% 492,468
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lexeo Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.130USD
Average target price
20.30USD
Spread / Average Target
+548.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lexeo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. LXEO Stock